drugset / Trial / NCT00752882

Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration

NCT00752882

Phase 2 Unknown 24 enrolled University Hospital, Clermont-Ferrand
RandomizedSingle-groupSingle-blindTreatment

Summary

Meningitis is an infection where morbidity and mortality depend on the delay of the initial treatment for a good prognostic. The antibiotherapy rapidity allows to decrease the mortality. Intermittent administration of ceftazidime is a reference treatment of Pseudomonas aeruginosa meningitis. In the case of Pseudomonas aeruginosa pneumopathy, ceftazidime can be administered by intermittent injections or by continuous perfusion. The continuous administration of ceftazidime is not validated in Pseudomonas aeruginosa meningitis. However, ceftazidime is a time dependant antibiotic and continuous treatment would provide a more efficient therapeutic. The aim of this study is to determine if the continuous administration of ceftazidime could permit a better therapeutic practice of Pseudomonas aeruginosa meningitis compared with intermittent administrations.

Timeline

Start
Primary completion
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftazidime Small molecule 29 mg/kg Intravenous
Subject Ceftazidime Small molecule 86 mg/kg Intravenous